Suppr超能文献

用于治疗累及石丸2区和3区的主动脉疾病的带窗主动脉弓腔内修复术

Fenestrated Aortic Arch Endovascular Repair for Aortic Diseases Extending to Ishimaru Zones 2 and 3.

作者信息

Nana Petroula, Panuccio Giuseppe, Torrealba José I, Rohlffs Fiona, Kölbel Tilo

机构信息

German Aortic Center, Department of Vascular Medicine, University Heart and Vascular Center UKE Hamburg, Hamburg, Germany.

Department of Vascular Surgery, University Hospital Regensburg, Regensburg, Germany.

出版信息

J Endovasc Ther. 2025 Mar 18:15266028251324826. doi: 10.1177/15266028251324826.

Abstract

INTRODUCTION

Fenestrated endovascular aortic arch repair (fTEVAR) has been successfully used for the exclusion of aortic lesions extending to distal arch. This study aimed to present the outcomes of fTEVAR for the preservation of the left common carotid artery (LCCA) or left subclavian artery (LSA) in lesions extending to Ishimaru zone 2 and 3.

MATERIALS AND METHODS

A single-center retrospective analysis of patients managed with fTEVAR for the preservation of the LCCA or LSA, between September 1st, 2011 and December 31st, 2023, was conducted, following the STROBE guidelines. Only preloaded fenestrated custom-made devices (Cook Medical, Bloomington, IN, USA) were used. Primary outcomes were technical success, mortality, and stroke at 30 days. Survival and freedom from secondary intervention were assessed using Kaplan-Meier estimates.

RESULTS

Seventy-five patients were included [72 years (IQR 13), range 48-86; 66.7% males]; 54 scheduled for LSA and 21 for LCCA preservation. Seven (9.3%) were treated urgently. Twenty-one (28.0%) presented with aortic dissection; 19 type B. Ishimaru zone 2 disease extension was recorded in 44 (58.7%) and zone 3 in 32 (42.7%). Debranching was performed in 22 patients: 81.8% LCCA-LSA bypass. Technical success was 93.3% with proximal landing to zone 0 in 18.7% cases, zone 1 in 70.7%, and zone 2 in 10.6%. Six (8.0%) deaths were recorded at 30-days and 4 (5.3%) strokes; 2 (2.7%) major. All strokes were diagnosed in patients with LCCA preservation. The multivariate analysis showed LCCA bridging (OR 0.2, 95% CI 0.08-0.3, p < 0.001) as independently related to stroke. The median follow-up was 12 months. The survival and freedom from secondary intervention were 85.2% [standard error (SE) 4.7%] and 75.0% (SE 6.5%) at 12 months, respectively.

CONCLUSION

Patients treated by fTEVAR for diseases extending to zones 2 and 3 presented encouraging early outcomes. LCCA bridging seems to be independently related to higher stroke rate. Preservation of the LSA seems safe, without neurological consequences.Clinical ImpactFenestrated endovascular arch repair has been applied with acceptable mortality in distal aortic arch lesions. However, the published experience is limited. This retrospective study of 75 patients with disease extend to zones 2 and 3 showed encouraging early outcomes with 93.3% technical success, 8.0% mortality, and 5.3% strokes. The inclusion of the left common carotid artery to the repair was related to higher stroke rate, while the preservation of the left subclavian seems to have no neurological consequences.

摘要

引言

开窗式血管腔内主动脉弓修复术(fTEVAR)已成功用于排除延伸至主动脉弓远端的病变。本研究旨在介绍fTEVAR在保留延伸至Ishimaru 2区和3区病变中的左颈总动脉(LCCA)或左锁骨下动脉(LSA)方面的结果。

材料与方法

按照STROBE指南,对2011年9月1日至2023年12月31日期间接受fTEVAR治疗以保留LCCA或LSA的患者进行单中心回顾性分析。仅使用预加载的定制开窗装置(美国印第安纳州布卢明顿市库克医疗公司)。主要结局为30天时的技术成功率、死亡率和卒中发生率。使用Kaplan-Meier估计法评估生存率和免于二次干预的情况。

结果

纳入75例患者[年龄72岁(四分位间距13),范围48 - 86岁;66.7%为男性];54例计划保留LSA,21例计划保留LCCA。7例(9.3%)为急诊治疗。21例(28.0%)表现为主动脉夹层;19例为B型。Ishimaru 2区病变扩展记录于44例(58.7%),3区记录于32例(42.7%)。22例患者进行了去分支手术:81.8%为LCCA - LSA旁路手术。技术成功率为93.3%,近端锚定至0区的病例占18.7%,1区占70.7%,2区占10.6%。30天时记录到6例(8.0%)死亡和4例(5.3%)卒中;2例(2.7%)为严重卒中。所有卒中均在保留LCCA的患者中诊断出。多变量分析显示LCCA搭桥(比值比0.2,95%置信区间0.08 - 0.3,p < 0.001)与卒中独立相关。中位随访时间为12个月。12个月时的生存率和免于二次干预率分别为85.2%[标准误(SE)4.7%]和75.0%(SE 6.5%)。

结论

接受fTEVAR治疗病变延伸至2区和3区的患者呈现出令人鼓舞的早期结果。LCCA搭桥似乎与较高的卒中发生率独立相关。保留LSA似乎是安全的,无神经学后果。临床影响开窗式血管腔内主动脉弓修复术应用于主动脉弓远端病变时死亡率可接受。然而,已发表的经验有限。这项对75例病变延伸至2区和3区患者的回顾性研究显示了令人鼓舞的早期结果,技术成功率为93.3%,死亡率为8.0%,卒中发生率为5.3%。修复术中纳入左颈总动脉与较高的卒中发生率相关,而保留左锁骨下动脉似乎无神经学后果。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验